A-Alpha Bio is building a high-resolution model of biology by measuring protein interactions.

A-Alpha leverages its platform technology AlphaSeq to generate high-quality protein interaction data at scale, enabling the discovery of better drugs faster.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • David Younger
  • Randolph Lopez

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • "The partnership is the first announced by A-Alpha Bio in the cutting-edge and rapidly growing area of targeted pro… https://t.co/cjwRHCBH4v@AAlphaBio - 05:05 PM Dec 22nd
  • We're delighted to share that we have partnered with @KymeraTx to take on the field of targeted protein degradation… https://t.co/iqV7Slp0fa@AAlphaBio - 04:47 PM Dec 16th
  • We are thrilled to announce that Padma Kodukula has joined A-Alpha Bio as Chief Business Officer! Padma will play t… https://t.co/1A99iCe4aX@AAlphaBio - 04:10 PM Nov 30th